259 related articles for article (PubMed ID: 667791)
1. Effects of radiochemotherapy and splenectomy on cellular immunity in long-term survivors of Hodgkin's disease and non-Hodgkin's lymphoma.
Steele R; Han T
Cancer; 1978 Jul; 42(1):133-9. PubMed ID: 667791
[TBL] [Abstract][Full Text] [Related]
2. B lymphocytes in untreated patients with malignant lymphoma and Hodgkin's disease.
Gajl-Peczalska KJ; Hansen JA; Bloomfield CD; Good RA
J Clin Invest; 1973 Dec; 52(12):3064-73. PubMed ID: 4201499
[TBL] [Abstract][Full Text] [Related]
3. The influence of splenectomy on the invitro lymphocyte response to phytohemagglutinin and pokeweed mitogen in Hodgkin's disease.
Wagener DJ; Geestman E; Wessels HM
Cancer; 1975 Jul; 36(1):194-8. PubMed ID: 1203846
[TBL] [Abstract][Full Text] [Related]
4. [Effect of radiochemotherapy and splenectomy on lymphoid subclasses in patients with Hodgkin's lymphoma in complete remission].
Leoni P; Montroni M; Montillo M; Salvi A; Centurioni R; Fanciulli E
G Clin Med; 1981 Oct; 62(10):685-92. PubMed ID: 6977469
[No Abstract] [Full Text] [Related]
5. A micro-method for PHA-induced stimulation of human lymphocytes. II. communication: effect of splenectomy on the inhibitory activity of serum in patients with Hodgkin's disease.
Pappas A; Pees H; Girmann G
Z Immunitatsforsch Immunobiol; 1977 Apr; 153(1):1-10. PubMed ID: 868205
[TBL] [Abstract][Full Text] [Related]
6. The potential benefits of therapeutic splenectomy for patients with Hodgkin's disease and non-Hodgkin's lymphomas.
Schreiber DP; Jacobs C; Rosenberg SA; Cox RS; Hoppe RT
Int J Radiat Oncol Biol Phys; 1985 Jan; 11(1):31-6. PubMed ID: 3838166
[TBL] [Abstract][Full Text] [Related]
7. The influence of splenectomy on cellular immunologic parameters in Hodgkin's disease.
Wagener DJ; Geestman E; Borgonjen A; Haanen C
Cancer; 1976 May; 37(5):2212-9. PubMed ID: 130968
[TBL] [Abstract][Full Text] [Related]
8. In vitro lymphocyte response to the phytomitogens in untreated and treated patients with Hodgkin's disease.
Romagnani S; Amadori A; Biti G; Bellesi G; Ricci M
Int Arch Allergy Appl Immunol; 1976; 51(3):378-89. PubMed ID: 1279027
[TBL] [Abstract][Full Text] [Related]
9. The immediate effects of splenectomy, radiotherapy and intensive chemotherapy on the immune status of patients with malignant lymphoma.
Hancock BW; Bruce L; Ward AM; Richmond J
Clin Oncol; 1977 Jun; 3(2):137-44. PubMed ID: 872467
[No Abstract] [Full Text] [Related]
10. Transfer factor in Hodgkin's disease.
Ng RP; Moran CJ; Alexopoulos CG; Bellingham AJ
Lancet; 1975 Nov; 2(7941):901-3. PubMed ID: 53376
[TBL] [Abstract][Full Text] [Related]
11. [Proportions and absolute count of T- and B-lymphocytes in peripheral blood and their blastic transformation induced by mitogens in splenectomized and non-splenectomized patients with Hodgkin's disease].
Pluzańska A
Acta Haematol Pol; 1978; 9(1):37-44. PubMed ID: 307325
[TBL] [Abstract][Full Text] [Related]
12. Restoration of cellular immune response by levamisole in patients with Hodgkin's disease.
Levo Y; Rotter V; Ramot B
Biomedicine; 1975 Jun; 23(6):198-200. PubMed ID: 1082352
[TBL] [Abstract][Full Text] [Related]
13. Long-term influence of splenectomy on immune functions in patients with Hodgkin's disease.
Björkholm M; Askergren J; Holm G; Mellstedt H
Scand J Haematol; 1980 Jan; 24(1):87-94. PubMed ID: 6966069
[TBL] [Abstract][Full Text] [Related]
14. Lymphocyte subpopulations in Hodgkin's disease and non-Hodgkin's lymphoma and the effects of radiotherapy.
Balasem AN; Barker CR
Clin Radiol; 1984 Sep; 35(5):353-7. PubMed ID: 6236011
[TBL] [Abstract][Full Text] [Related]
15. Influence of splenectomy upon immunologic reactivity of patients with Hodgkin's disease.
Rogan-Grgas J; Milas L; Hauptmann E; Nola P; Kolarić K; Maricić Z; Malenica B
Tumori; 1981 Dec; 67(6):539-47. PubMed ID: 6977906
[TBL] [Abstract][Full Text] [Related]
16. Splenic T and B lymphocytes and their mitogenic response in untreated Hodgkin's disease.
Han T; Minowada J; Subramanian V; Barcos M; Kim U
Cancer; 1980 Feb; 45(4):767-74. PubMed ID: 6965606
[TBL] [Abstract][Full Text] [Related]
17. Immunity in Hodgkin's disease: status after 5 years' remission.
Hancock BW; Bruce L; Whitham MD; Dunsmore IR; Ward AM; Richmond J
Br J Cancer; 1982 Oct; 46(4):593-600. PubMed ID: 7138765
[TBL] [Abstract][Full Text] [Related]
18. Quantitation of T and B lymphocytes and cellular immune function in Hodgkin's disease.
Bobrove AM; Fuks Z; Strober S; Kaplan HS
Cancer; 1975 Jul; 36(1):169-79. PubMed ID: 54208
[TBL] [Abstract][Full Text] [Related]
19. In vitro evidence of normal lymphocyte function in some patients with Hodgkin's disease and negative delayed cutaneous hypersensitivity.
Churchill WH; Rocklin RR; Moloney WC; David JR
Natl Cancer Inst Monogr; 1973 May; 36():99-106. PubMed ID: 4583000
[No Abstract] [Full Text] [Related]
20. Risk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology and stage of Hodgkin's disease, and splenectomy.
Swerdlow AJ; Douglas AJ; Vaughan Hudson G; Vaughan Hudson B; MacLennan KA
Br J Cancer; 1993 Nov; 68(5):1006-11. PubMed ID: 8217588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
